Creative Medical Technology Holdings (CELZ) Change in Accured Expenses (2010 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly Change in Accured Expenses of -$39920.0 for Q1 2025, down 1230.67% quarter-over-quarter from -$3000.0 in Q4 2024.
Creative Medical Technology Holdings (CELZ) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Change in Accured Expenses for 15 consecutive years, with -$39920.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Change in Accured Expenses changed N/A year-over-year to -$39920.0; the TTM figure through Dec 2025 stood at -$39920.0 (changed N/A YoY), while the FY2025 annual figure was -$39920.0, changed N/A from the prior year.
- Change in Accured Expenses eased to -$39920.0 in Q1 2025 per CELZ's latest filing, from -$3000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $35000.0 in Q2 2022 and bottomed at -$39920.0 in Q1 2025.
- Historically, Change in Accured Expenses has averaged -$340.91 across 4 years, with a median of $814.0 in 2021.
- On a YoY basis, Change in Accured Expenses climbed as much as 114.34% in 2022 and fell as far as 1328.5% in 2022.
- Creative Medical Technology Holdings' Change in Accured Expenses stood at -$5534.0 in 2021, then sank by 171.05% to -$15000.0 in 2022, then soared by 80.0% to -$3000.0 in 2024, then plunged by 1230.67% to -$39920.0 in 2025.
- Business Quant data shows CELZ's Change in Accured Expenses at -$39920.0 in Q1 2025, -$3000.0 in Q4 2024, and $3000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -39,920.00 |
| Mar 31, 2025 | -39,920.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Dec 31, 2022 | -15,000.00 |
| Dec 31, 2022 | -15,000.00 |
| Sep 30, 2022 | -10,000.00 |
| Sep 30, 2022 | -10,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Mar 31, 2022 | 5,535.00 |
| Mar 31, 2022 | 5,535.00 |
| Dec 31, 2021 | -5,534.00 |
| Dec 31, 2021 | -5,534.00 |
| Sep 30, 2021 | 814.00 |
| Sep 30, 2021 | 814.00 |
| Jun 30, 2021 | 16,329.00 |
| Jun 30, 2021 | 16,329.00 |